|Bid||305.00 x 900|
|Ask||311.18 x 1100|
|Day's Range||307.10 - 313.19|
|52 Week Range||261.61 - 372.61|
|Beta (3Y Monthly)||1.34|
|PE Ratio (TTM)||53.78|
|Earnings Date||Jul 29, 2019 - Aug 2, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||343.08|
The region, with eight research intensive universities, is home to a £13.6bn industry and 21 per cent of the total UK life science sector workforce, according to the Northern Health Science Alliance. Some are now showing signs of health. share price into the doldrums, this year is proving more positive for the pharmaceuticals company behind iron deficiency drug Feraccru.
Illumina, Inc. today announced that it has filed another patent infringement suit against one of BGI Group’s subsidiaries, BGI Europe A/S. Illumina filed suit in the Maritime & Commercial High Court of Denmark.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
One of the biggest investment opportunities over the next decade will be in companies working to delay human death, a market expected to be worth at least $600 billion by 2025, according to Bank of America analysts. One of the biggest investment opportunities over the next decade will be in companies working to delay human death, a market expected to be worth at least $600 billion by 2025, according to one of Wall Street's major investment banks.
Some testing firms are finding it works better when health-care providers are more directly involved. Helix, which launched in 2015 with $100 million from genome-sequencing giant Illumina Inc., had planned to sell tests directly through an “app store’’ for DNA. Instead, it’s now looking to partner with health-care providers.
LAS VEGAS, May 7, 2019 /PRNewswire/ -- The Healthy Nevada Project, a first-of-its-kind, community-based population health study combining genetic, clinical, environmental and social data, is expanding enrollment to Las Vegas. The Project aspires not only to offer genetic testing to every Nevadan interested in learning more about their health and genetic profile but ultimately, to develop and expand the Project for communities across the United States to drive positive health outcomes nationwide.
Illumina Inc NASDAQ/NGS:ILMNView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for ILMN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ILMN totaled $5.28 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Illumina, Inc. (ILMN) today announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast. The live webcast can be accessed in the Investor Relations section of Illumina's web site under the "company" tab at www.illumina.com. A replay of the presentation will be posted on Illumina’s web site after the event and will be available for at least 30 days following.
Companies that invested heavily in buybacks saw their shares rise just 7% in 12 months, versus a 13% gain for the S&P 500, per Goldman Sachs.
Illumina's (ILMN) NextSeq and MiSeq placements witness year-over-year growth, with the strength of the former being driven by solid demand for TSO500.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 25) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ...
The gene-sequencing leader's revenue and earnings growth rates slowed down in the first quarter, but stronger growth is likely on the way.
Illumina and PerkinElmer earnings beat first-quarter expectations when the two reported results late Thursday. But Illumina and PerkinElmer shares stumbled in action after the close.